TY - JOUR
T1 - What lurks beneath
T2 - IL-11, via Stat3, promotes inflammation-associated gastric tumorigenesis
AU - Merchant, Juanita L.
PY - 2008/5/1
Y1 - 2008/5/1
N2 - Chronic inflammation in the stomach induces cellular transformation and gastric cancer primarily in the distal stomach or antrum. In this issue of the JCI, a study in mice by Ernst et al. provides new insight into the role of IL-11 and its glycoprotein 130 (gp130) receptor in inflammation-associated gastric epithelial cell oncogenic transformation, which they show is mediated by and dependent on increased activation of Stat3 and, to a lesser extent, Stat1 (see the related article beginning on page 1727). Prior studies from this group have shown that Stat3 hyperactivity stimulates the TGF-β inhibitor Smad7. Collectively, the studies suggest that an important pathway of oncogenic transformation in the stomach is through suppression of growth inhibitory signals, such as members of the TGF-β family, that originate from the stroma.
AB - Chronic inflammation in the stomach induces cellular transformation and gastric cancer primarily in the distal stomach or antrum. In this issue of the JCI, a study in mice by Ernst et al. provides new insight into the role of IL-11 and its glycoprotein 130 (gp130) receptor in inflammation-associated gastric epithelial cell oncogenic transformation, which they show is mediated by and dependent on increased activation of Stat3 and, to a lesser extent, Stat1 (see the related article beginning on page 1727). Prior studies from this group have shown that Stat3 hyperactivity stimulates the TGF-β inhibitor Smad7. Collectively, the studies suggest that an important pathway of oncogenic transformation in the stomach is through suppression of growth inhibitory signals, such as members of the TGF-β family, that originate from the stroma.
UR - http://www.scopus.com/inward/record.url?scp=43049113155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43049113155&partnerID=8YFLogxK
U2 - 10.1172/JCI35344
DO - 10.1172/JCI35344
M3 - Comment/debate
C2 - 18431518
SN - 0021-9738
VL - 118
SP - 1628
EP - 1631
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 5
ER -